Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation
Overview
Authors
Affiliations
The PKR protein kinase is a critical component of the cellular antiviral and antiproliferative responses induced by interferons. Recent evidence indicates that the nonstructural 5A (NS5A) protein of hepatitis C virus (HCV) can repress PKR function in vivo, possibly allowing HCV to escape the antiviral effects of interferon. NS5A presents a unique tool by which to study the molecular mechanisms of PKR regulation in that mutations within a region of NS5A, termed the interferon sensitivity-determining region (ISDR), are associated with sensitivity of HCV to the antiviral effects of interferon. In this study, we investigated the mechanisms of NS5A-mediated PKR regulation and the effect of ISDR mutations on this regulatory process. We observed that the NS5A ISDR, though necessary, was not sufficient for PKR interactions; we found that an additional 26 amino acids (aa) carboxyl to the ISDR were required for NS5A-PKR complex formation. Conversely, we localized NS5A binding to within PKR aa 244 to 296, recently recognized as a PKR dimerization domain. Consistent with this observation, we found that NS5A from interferon-resistant HCV genotype 1b disrupted kinase dimerization in vivo. NS5A-mediated disruption of PKR dimerization resulted in repression of PKR function and inhibition of PKR-mediated eIF-2alpha phosphorylation. Introduction of multiple ISDR mutations abrogated the ability of NS5A to bind to PKR in mammalian cells and to inhibit PKR in a yeast functional assay. These results indicate that mutations within the PKR-binding region of NS5A, including those within the ISDR, can disrupt the NS5A-PKR interaction, possibly rendering HCV sensitive to the antiviral effects of interferon. We propose a model of PKR regulation by NS5A which may have implications for therapeutic strategies against HCV.
Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy.
Ke P, Yeh C Pathogens. 2024; 13(11).
PMID: 39599533 PMC: 11597459. DOI: 10.3390/pathogens13110980.
Frericks N, Brown R, Reinecke B, Herrmann M, Bruggemann Y, Todt D J Virol. 2024; 98(3):e0192123.
PMID: 38319104 PMC: 10949430. DOI: 10.1128/jvi.01921-23.
Barik S Int J Mol Sci. 2023; 24(22).
PMID: 38003289 PMC: 10671098. DOI: 10.3390/ijms242216100.
Guo L, Hu C, Liu Y, Chen X, Song D, Shen R Nat Commun. 2023; 14(1):3410.
PMID: 37296165 PMC: 10256765. DOI: 10.1038/s41467-023-39156-3.
NS5A domain I antagonises PKR to facilitate the assembly of infectious hepatitis C virus particles.
Chen S, Harris M PLoS Pathog. 2023; 19(2):e1010812.
PMID: 36795772 PMC: 9977016. DOI: 10.1371/journal.ppat.1010812.